N/A
N=9,375
The Outreach and Prevention at ALcohol Venues in East Africa Study (OPAL-East Africa- Aim 1)
HIV/AIDS
Bottom Line
View on ClinicalTrials.gov: NCT05862857 ↗Enrolled (actual)
9,375
Serious AEs
0.0%
Results posted
Mar 2026
Primary outcome: Primary: Biomedical HIV Prevention Uptake at 4 Weeks — 23.7; 24.1 % of participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- HIV-focused mobilization (Behavioral); Multi-disease-focused mobilization (Behavioral)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- University of California, San Francisco
- Primary completion
- Feb 2025
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Biomedical HIV Prevention Uptake at 4 Weeks |
23.7; 24.1 | — |
| SECONDARY Biomedical HIV Prevention Uptake at 8 Weeks |
23.8; 24.1 | — |
| SECONDARY Biomedical HIV Prevention Uptake at 12 Weeks |
23.8; 24.1 | — |
| SECONDARY HIV Testing Uptake |
— | — |
| SECONDARY Yield of Adults With Untreated HIV |
— | — |
| SECONDARY Yield of Adults With Heavy Alcohol Use |
— | — |
| SECONDARY Adults With Untreated HIV Who Initiate ART |
— | — |
Summary
This study will test innovative interventions to increase uptake and use of biomedical HIV prevention options by engaging women and men at drinking venues in rural Kenya and Uganda in care, while gaining insights into the facilitators, barriers, and cost-effectiveness of these approaches.
Eligibility Criteria
Participant Inclusion Criteria:
- adult (≥18 years)
- patron or worker at a drinking venue within the study community
Exclusion Criteria
- none
Data sourced from ClinicalTrials.gov (NCT05862857). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.